Jasper Therapeutics repoirts data from its SPOTLIGHT study of briquilimab

Jasper Therapeutics reported preliminary data from the Company’s ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with cold urticaria or symptomatic dermographism, the two most prevalent sub types of CIndU. 14 of 15 participants enrolled in both dose cohorts of the study achieved a clinical response within the 6-week preliminary analysis period following administration. In the 120mg dose cohort, 10 of 12 participants experienced a complete response, and 1 participant experienced a partial response. Briquilimab was well tolerated in the study, with no serious adverse events and no grade 3 or higher adverse events reported. In alignment with the Company’s clinical development plan, Jasper has obtained regulatory clearance to enroll a 180mg dose cohort in the SPOTLIGHT study. Jasper expects to present full data from the SPOTLIGHT study in the first half of 2025. Briquilimab was well tolerated in the study. No SAEs or AEs grade 3 were reported. Furthermore, there were no reported AEs related to hair or skin color changes, hypersensitivity, or anemia. Mild decreases in neutrophil counts were observed, with no participants experiencing neutrophil counts below 1500.